Home » Newsletters » BioWorld Science

BioWorld Science

July 14, 2021

View Archived Issues

Patient recruitment ongoing in two phase I/II trials of TQ-05105 in GvHD

Enrollment ongoing in phase II study of ISA-101b vaccine plus cemiplimab in HPV16 cervical cancer

Tyrosine-protein kinase ITK/TSK inhibitors discovered at Pfizer

Roche, Monash University describe IL-37 fusion proteins

Genfit presents prodrugs of nuclear receptor ROR-gamma modulators

Janssen Pharmaceutica discovers menin/MLL interaction inhibitors

ERK-1/2 inhibitor GIZH298 demonstrates antiseizure effects in vivo

VRG-101: a new PIKfyve inhibitor for SARS-CoV-2

AR-712 MAb cocktail neutralizes SARS-CoV-2 Delta variant

Ionis and Bicycle Therapeutics enter licensing agreement to advance LICA technology

miR-491-5p and miR-592 are downregulated in overactive bladder

PAT-DX3 shows the ability to cross blood-brain barrier in models of GBM

Hepion reports phase IIa topline data on CRV-431 in presumed F2 and F3 NASH

Genocea initiates phase I/IIa study of neoantigen-targeted T cell therapy GEN-011

XVR-011 shows neutralization activity against the Gamma and Delta variants of SARS-CoV-2

ACE2 and TLR7 are highly expressed in severe patients with COVID-19

SFX-01 shown to be effective in in vitro models of blood cancers

First cohort of subjects dosed in ASC-42 bridging study in China

FDA clears IND for Kintor's GT-20029 for androgenetic alopecia and acne

Barcoding strategy tracks breast cancer metastases

ENA studies INNA-051 nasal spray in phase I to boost innate immunity against respiratory viruses

TP-03 enhances the stimulating effect of hCG on testicular steroidogenesis

Oryzon cleared to begin phase IIb trial of vafidemstat in schizophrenia

Valo submits CTA for first-in-human study of PeptiCRAd-1 in melanoma, TNBC and NSCLC

Oral fadraciclib enters phase I/II study in advanced solid tumors

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...